Table 3 Rates of adverse events of interest through 3 years of treatment
AE | Overall safety population (n = 190; 412.2 patient-years) | MRI/CRP-positive safety subpopulation (n = 145; 320.9 patient-years) | ||
|---|---|---|---|---|
No. (%) | Events/100 patient-years | No. (%) | Events/100 patient-years | |
Serious AEs | 33 (17.4) | 10.9 | 25 (17.2) | 9.7 |
Serious infection | 8 (4.2) | 2.4 | 6 (4.1) | 2.2 |
Tuberculosis | 1 (0.5) | 0.2 | 1 (0.7) | 0.3 |
Lupus-like reaction and systemic lupus erythematosus | 1 (0.5) | 0.2 | 1 (0.7) | 0.3 |
Pulmonary embolism | 1 (0.5) | 0.2 | 1 (0.7) | 0.3 |
New-onset psoriasis | 2 (1.1) | 0.5 | 1 (0.7) | 0.3 |
Hepatic-related AEs | 2 (1.1) | 0.5 | 1 (0.7) | 0.3 |
Diverticulitis | 1 (0.5) | 0.2 | 1 (0.7) | 0.3 |
Death | 2 (1.1) | 0.5 | 2 (1.4) | 0.6 |